Whole Body Activity Retentions in the Peptide Receptor Radionuclide Therapy with Lu-177

The patients with the neuroendocrine tumours (liver, spleen, etc.) often need treatment by the Peptide Receptor Radionuclide Therapy with 177Lu. The amount of 177Lu activity in the body of patients has to be known accurately for assessment of the dosimetry and for evaluation of the effectiveness of the therapy. Whole-body activities at the given...